China innovative drug stocks rally; Jinling Pharma, Guilin Sanjin hit limit up

The uniformity of the move — limit-ups at the small-cap end alongside 5%-plus gains for larger names like BeiGene — points to sector-wide positioning rather than company-specific news, which makes the rally a sentiment signal more than a fundamental one. For China biotech watchers, the key question is whether this breadth persists in a session the item itself describes as volatile, since limit-up moves at thinly traded names can overstate conviction. Whether the gains hold across the larger, more liquid listings is the open question.